Manon MJ van den Berg MSc
event_seat PhD Student
account_balance UNS50 F4.126
Manon van den Berg was born on December 13th 1993 in Madrid, Spain. She moved a couple times back and forth from Spain to the Netherlands, but has remained in the Netherlands since 2007. She graduated cum laude for her bachelor ‘Biomedical Sciences’ with specialization ‘Molecular Life Sciences’ at Maastricht University in 2015. Her bachelor internship was under the supervision of Dr. Cora Nijboer at the Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD) at the Wilhelmina Children’s Hospital in Utrecht, the Netherlands. She was researching the effect of maternal inflammation and transient hypoxia on glia cells in preterm infants. Her project aided to understand the underlying pathophysiology of Diffuse White Matter Injury.
She proceeded her studies at Maastricht University and graduated cum laude for the research master ‘Cognitive and Clinical Neuroscience’ with specialization ‘Fundamental Neuroscience’ in 2017. She had done her master internship at Columbia University in New York City under the supervision of Prof. Dr. Ottavio Arancio at the TAUB institute. During this period, she was measuring long term potentiation (LTP) in hippocampal slices. She was investigating whether different components in the NO cascade impinging on CREB phosphorylation are involved in the amelioration of abnormal synaptic plasticity caused by tau pathology.
In January 2018 she has started her PhD at Maastricht University. She is part of the ‘Center of Integrative Neuroscience’(CIN) project. Her PhD project is a collaboration between the two faculties FHML and FPN. She will be working in the group of Prof. Dr. Jos Kleinjans (FHML, department Toxicogenomics), Prof. Dr. Jos Prickaerts (FHML, department Psychiatry and Neuropsychology and Prof. Dr. Jan Raemakers (FPN, department Neuropsychology and Psychopharmacology). Her research will focus on brain miRNA as markers of drug induced changes in neural integrity, for both humans and rodents.
Testing mechanistic and placebo-controlled studies in which we will administer a psychedelic drug (i.e. psilocybin) that is known to affect neural integrity More »